# Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

> **NCT00899353** · PHASE2 · TERMINATED · sponsor: **Marshall University** · enrollment: 16 (actual)

## Conditions studied

- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Multiple Myeloma
- Chronic Lymphocytic Leukemia

## Interventions

- **DIETARY_SUPPLEMENT:** Omega 3 Fatty Acid

## Key facts

- **NCT ID:** NCT00899353
- **Lead sponsor:** Marshall University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2012-10
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Original Principal Investigator left the institution.
- **Last updated:** 2013-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00899353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00899353, "Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00899353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*